theheart.org: Acute Coronary Syndromes (ACS) news and education

Acute Coronary Syndromes

Oct 30, 2009 10:23 EDT

PLATO, CURRENT-OASIS 7, and further analyses of PPIs and thienopyridines; read Dr Prasad's review of recent data presented at ESC; and watch presentations by Drs Mehran, O'Donoghue, Storey, and Wiviott.

Acute Coronary Syndromes

Tips and Approaches to Reducing Bleeding in PCI

1 COMMENT - Oct 29, 2009 10:37 EDT

Join Drs. Bhatt, Rao, and Stone as they discuss important clinical trial data which will improve management strategies for patients undergoing PCI.

Acute Coronary Syndromes

The Role of Antiplatelet Therapy in the Management of Patients with NSTE ACS

Oct 28, 2009 10:46 EDT

In the US, each year over 1.4 million people will be hospitalized for unstable angina (UA) and non-ST-segment-elevation myocardial infarction (NSTEMI). Multiple antiplatelet agents have been developed to interfere with or inhibit the specific pathways of platelet activation and aggregation that lead to the development of UA and NSTEMI. Join Drs Newby, Popma, and Wiviot as they discuss.

Acute Coronary Syndromes

Antiplatelet Therapy in ACS: The Latest Dialogues

Oct 15, 2009 16:09 EDT

PLATO, the ESC late-breaking trial, compared a novel direct-acting reversible P2Y12 antagonist with clopidogrel in ACS patients undergoing PCI. Dr. Keith Fox leads a discussion with the PI, Dr. Lars Wallentin, and Dr. Deepak Bhatt.

Interventional/Surgery

Dual Antiplatelet Therapy: Dueling Options in Real-World Practice

1 COMMENT - Sep 30, 2009 13:31 EDT

With the recent approval of a third-generation thienopyridine, choice of agent can be added to the list of considerations in the management of ACS patients, as well as the appropriate timing and dosing of thienopyridine. Using some case vignettes, Dr. King leads a discussion with Drs. Bhatt and Steg on their clinical decision-making.

Acute Coronary Syndromes

Best Practices for the Treatment of STEMI: How Can We Decrease Mortality?

Sep 21, 2009 09:56 EDT

Patients presenting with STEMI represent a high-risk population. Thrombotic and bleeding complications contribute to mortality in these patients. Join Drs. Steg, Hamm, Hill, and Mehran as they discuss best practices for the treatment of STEMI patients with a focus on preventing bleeding complications.

Acute Coronary Syndromes

In Brief: Optimal Use of Dual Antiplatelet Therapy...

Sep 15, 2009 15:44 EDT

Antiplatelet therapy is key for the prevention of secondary events in ACS patients. Dr. Ardissino introduces a series of brief presentations by Drs. Angiolillo, Fernánadez-Avilés, Montalescot, and Neumann on the optimal use of antiplatelets in ACS patients undergoing PCI, including those with diabetes and those at high bleeding risk.

Acute Coronary Syndromes

Antiplatelet Therapy in PCI: Addressing Unmet Needs

Aug 28, 2009 11:29 EDT

How will the prasugrel approval and the upcoming PLATO and CURRENT-OASIS 7 trials affect antiplatelet options for ACS patients undergoing PCI? Read a summary of the latest data, with expert input from Drs. Ardissino and Montalescot.

Acute Coronary Syndromes

Managing Bleeding Complications in PCI

Aug 12, 2009 13:40 EDT

A patient suffers a STEMI after exploratory laparotomy for suspected gastrinoma; their surgeon insists that no anticoagulation be given. How would you treat? Dr. Rao presents such a complicated case to Dr. Montalescot.

Acute Coronary Syndromes

Meeting the Challenges in Long-Term Anticoagulation: Opportunities to Improve Patient Care

Aug 7, 2009 09:10 EDT

Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.

Thrombosis Risk

Advancing Anticoagulation in Cardiovascular Medicine: Perspectives on Future Oral Therapies

3 COMMENTS - Jul 31, 2009 11:00 EDT

The treatment options for oral anticoagulation therapy are constantly evolving. Join our expert panel, Drs. Graham Turpie, Jessica L. Mega, Jeffrey Weitz, as they discuss the new data and clinical implications of new anticoagulant medications for patients with ACS

Acute Coronary Syndromes

Antiplatelet Therapy: A Brazilian Expert's Take

1 COMMENT - Jul 14, 2009 12:00 EDT

From SOLACI 2009 in Rio de Janeiro. Dr. Mahmud hears how Dr. Feres interprets the data on antiplatelet/antithrombin strategies for his practice in Brazil.

Acute Coronary Syndromes

Antiplatelet Therapy: The Latin American Perspective

Jul 1, 2009 13:57 EDT

HORIZONS-AMI has influenced US practice; after TRITON-TIMI 38, the potential role of prasugrel is a hot topic. How has Latin America responded to these data? Recorded at SOLACI 2009, Dr. Mahmud has an information exchange on contemporary antiplatelet management with two of Argentina's leading interventionalists, Drs. Grinfeld and Londero.

Acute Coronary Syndromes

Managing ACS: Exploring Evolving Options for Antiplatelet and Anticoagulant Therapy

2 COMMENTS - Jun 23, 2009 10:38 EDT

As innovative research expands and unfolds, management of the patient with acute coronary syndrome continually takes on new dimensions. Join Dr. Eugene Braunwald and other experts as they delve into current and future pharmacotherapeutic strategies and issues surrounding the best practices for ACS patients.

Clinical cardiology

New Data on Polyvascular Disease and ACS

1 COMMENT - Jun 23, 2009 09:40 EDT

Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.

Clinical cardiology

Combination Therapy and Cardiovascular Events: A Neurologist's Perspective

1 COMMENT - Jun 17, 2009 11:48 EDT

AF can lead to stroke, congestive heart failure, and other serious complications. Successful management should include reducing these risks. Join our expert panel, Drs. Peter Rothwell, Donald Easton, and Mark Alberts, as they discuss new data and strategies for improving outcomes in patients with AF.

Acute Coronary Syndromes

IIb or Not IIb: The Role of GP IIb/IIIa Inhibitors in ACS

Jun 15, 2009 13:47 EDT

After EARLY-ACS and HORIZONS-AMI, the utility of routine GP IIb/IIIa inhibitors in contemporary management of ACS patients has been challenged. Studies of prehospital and pre-angiography administration have yielded mixed results, largely reflecting different trial designs. Dr. Gershlick aims to clarify matters with Drs. Hamm and Mehran.

Acute Coronary Syndromes

Management of Antithrombotic Therapy and Bleeding in STEMI Patients

Jun 12, 2009 15:10 EDT

Studies suggest that major bleeding is associated with a 5-fold increase in the risk for death among ACS patients. Join our expert panel: Profs. Hamm, Kristensen, and Spaulding as they discuss treatment options and strategies to reduce bleeding in STEMI patients.

Clinical cardiology

2009 Antiplatelet Debate: What's New in ACS

5 COMMENTS - Jun 12, 2009 15:03 EDT

Despite modern therapy, the rates of death, MI, bleeding, and readmission remain high in patients with ACS. Join Drs. Jeffery Popma, Héctor Bueno, Freek Verheugt, and Sunil. Rao for a review of the latest data on antiplatelet therapy for patients with ACS.

Acute Coronary Syndromes

iQandA Interactive Medical Intelligence Zone for Interventional Cardiology

Jun 5, 2009 09:56 EDT

iQandA, The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.

Arrhythmia/EP

The Future of Ambulatory Monitoring: Moving Beyond Rate and Rhythm to Monitor ST-Segment Shifts

1 COMMENT - May 29, 2009 12:00 EDT

How can we reduce the time taken to accurately diagnose ACS? ECGs and biomarkers may be nondiagnostic, even the presenting symptoms can vary or be absent. As every 30 minutes delay is associated with a 7.5% relative increase in mortality, time is indeed muscle. Join Drs. Gibson, Pride, Santini, and Krucoff as they present new insights into this complex field.

Acute Coronary Syndromes

Antiplatelet Therapy in an ACS Patient With Diabetes

May 5, 2009 00:00 EDT

Patients with diabetes have more reactive platelets and are also more likely to have a diminished response to antiplatelet therapy. Dr. Angiolillo presents Dr. Storey with a case illustrating issues in the management of antiplatelet therapy in an ACS patient with diabetes.

Acute Coronary Syndromes

Upstream Adjunctive Therapy: The Importance of Early Timing in the Treatment of NSTEMI

3 COMMENTS - Apr 29, 2009 00:00 EDT

Join Drs. Harrington, Gibson, and Bates as they discuss the difficult issues of antithrombotic choices and the medical management of patients with NSTEMI.

Clinical cardiology

Preventing Vascular Events in AF: What Is the Role of Antiplatelet Therapy?

3 COMMENTS - Apr 28, 2009 10:00 EDT

Atrial fibrillation (AF) is the most frequently occurring cardiac arrhythmia affecting some 2.2 million Americans with often serious clinical consequences.. Join Drs. Bhatt, Connolly and Camm for a discussion on the risk factors, management challenges, and new data on treatment options for patients with AF

Acute Coronary Syndromes

Antiplatelet Pharmacogenetics: Can We Tailor Therapy?

2 COMMENTS - Apr 23, 2009 00:00 EDT

Carriers of certain CYP genetic variants have lower levels of clopidogrel's active metabolite and experience higher rates of MACE. Could genotyping help optimize antiplatelet therapy? Common PPIs also inhibit CYP enzymes and may impair clopidogrel efficacy. Dr. Topol discusses recent data on these topics with Drs. Montalescot, Sabatine, and Simon.

	Yes, at greater than or equal to 100 mg/day
	Yes, at less than 100 mg/day
	No